Agreement Between Magnetic Resonance Imaging and Pathologic Findings in the Tumor Size Evaluation Before and After Neoadjuvant Chemotherapy Treatment: A Prospective Study. Issue 7 (1st September 2017)

• Record Type: Journal Article
• Authors: Cheng, Jinlong; Hou, Yan; Li, Junnan; Wang, Wenjie; Xu, Ye; Yang, Chunyan; Ma, Libing; Dhillon, Harman S.; Openkova, Margarita S.; Fan, Xin; Li, Zhenzi; Li, Kang; Lou, Ge
• Is Part Of: International journal of gynecological cancer. Volume 27:Issue 7(2017)
• Page Start: 1472
• Page End: 1479
• Publication Date: 2017-09-01
• Subjects: Agreement -- MRI -- Neoadjuvant chemotherapy -- Response; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1097/IGC.0000000000001038
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objectives: To compare the agreement between magnetic resonance imaging (MRI) results and postsurgical pathologic findings for tumor size evaluation in cervical cancer patients before and after neoadjuvant chemotherapy (NACT) treatment. Methods: The study analyzed the agreement between pretreatment MRI results and postsurgical pathologic findings about the tumor size in 100 cervical cancer patients without NACT and 397 cervical cancer patients with NACT, respectively. Results: In general, the agreement between pretreatment MRI results and postsurgical pathologic findings of tumor size was 0.855 (95% confidence interval [CI], 0.763–0.909) in cervical cancer patients without NACT, whereas the agreement between posttreatment MRI results and postsurgical pathologic findings was 0.503 (95% CI, 0.421–0.576). Only 62.72% (249/397) of patients who underwent NACT treatment have the same chemotherapy response evaluation results; the κ coefficient was 0.384(95% CI, 0.310–0.457) between posttreatment MRI and postsurgical pathologic findings. We still found International Federation of Gynecology and Obstetrics stage is associated with the chemotherapy response evaluation. Conclusions: Our data suggest that pretreatment MRI can be a surrogate indicator for postsurgical pathologic findings. However, posttreatment MRI could not be a surrogate indicator for postsurgical pathologic findings. The chemotherapy response evaluation based on only MRI is not so reliable. More indicators should be developed for chemotherapy response evaluation.